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Abstract
The objective of the present study was to assess safety and immune responses in gilts after
intradermal application of Porcilis® PRRS in two different application sites under field condi-
tions. Forty-four gilts were allocated to one of three groups: Gilts of group 1 (n = 10) served
as non-vaccinated controls, gilts of group 2 (n = 17) were vaccinated intradermally in the
neck and gilts of group 3 (n = 17) received an intradermal vaccination in the perianal region.
Clinical observations, local injection site reactions and histopathologic examination of the
injection site were used for safety assessments. Frequency and degree of clinical signs
were not significantly different between all three groups. Minor local reactions for both vacci-
nation groups were observed; however, at 6, 7, 8, 9 and 15 days post-vaccination (dpv), the
mean injection site reaction score was significantly lower in pigs vaccinated in the perianal
region. In histopathologic examination, an extended inflammatory dimension was observed
more frequently in pigs vaccinated in the neck. Blood samples were analyzed to quantify the
post-vaccination humoral (ELISA and virus neutralization test) and cellular (IFN-γ ELISPOT)
immune responses. PRRSV-specific antibodies were present in the serum of all vaccinated
animals from 14 dpv onwards, whereas all control pigs remained negative throughout the
study. Neutralizing antibody titers were significantly higher in pigs vaccinated in the perianal
region at 28 dpv. At 14, 21 and 28 dpv, PRRSV-specific IFN-γ secreting cells were signifi-
cantly increased in both vaccination groups compared to non-vaccinated gilts. Analysis of
mean numbers of PRRSV-specific IFN-γ secreting cells did not result in statistically signifi-
cant differences between both vaccination groups. The results of this study indicate that the
perianal region is a safe alternative application site for intradermal vaccination of gilts with
Porcilis PRRS. Furthermore, the intradermal application of Porcilis PRRS induced humoral
and cellular immune responses independent of the administration site.







Citation: Stadler J, Naderer L, Beffort L, Ritzmann
M, Emrich D, Hermanns W, et al. (2018) Safety and
immune responses after intradermal application of
Porcilis PRRS in either the neck or the perianal
region. PLoS ONE 13(9): e0203560. https://doi.
org/10.1371/journal.pone.0203560
Editor: Paulo Lee Ho, Instituto Butantan, BRAZIL
Received: February 9, 2018
Accepted: August 22, 2018
Published: September 7, 2018
Copyright: © 2018 Stadler et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Funding for the study was provided by
MSD Animal Health, Germany. The funders
provided support in the form of salaries for author
KF, but did not have any additional role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. The
specific role of this author is articulated in the
´author contributions‘section.
Introduction
The development of needle free injection systems dates back to the 1930s [1]. These devices
have been applied in human medicine for delivering insulin, anesthetics, growth hormones
and vaccines [2–5]. The skin, as a highly effective component of the immune system, is an
attractive target for vaccination due to its high density of immunocompetent cells such as
Langerhans cells and dermal dendritic cells that specialize in antigen uptake followed by
antigen presentation [6]. During the last decade, intradermal vaccination has also gained
increasing interest in veterinary medicine. The needle-free intradermal route of antigen
administration represents a less-invasive and less-painful alternative to conventional subcuta-
neous or intramuscular injections using a needle. Next to animal welfare improvement, addi-
tional merits of intradermal vaccination are its dose sparing capacity, reduction of iatrogenic
transmission of pathogens, elimination of the risk of inadvertent needle stick injuries and
improved meat quality due to the lack of needle-induced injection site lesions [7–9]. Accord-
ing to several investigations pigs have a high prevalence of injection site associated carcass
defects [10]. Condemnations of carcasses are not only attributed to broken needles but also to
abscesses and muscle damage. Currently, several commercially available vaccines against
swine-relevant pathogens (i.e. Mycoplasma (M.) hyopneumoniae, porcine reproductive and
respiratory syndrome virus (PRRSV), porcine circovirus 2, and pseudorabies virus) are
licensed for the intradermal needle-free delivery route.
PRRSV is considered to be one of the major pathogens in pigs and causes substantial eco-
nomic impact on the swine industry worldwide. Different strategies (i.e. management, test and
removal, vaccination) have been implemented in PRRSV-infected herds to control the disease.
A key component to reduce PRRSV-related reproductive and respiratory disorders is vaccina-
tion. Modified live virus vaccines have proven to be efficacious in reducing disease occurrence
and severity, as well as duration of viremia and virus shedding [11–13]. Several studies that
compare intradermal and intramuscular vaccination of PRRSV modified live virus suggest
that intradermal administration of PRRSV vaccines is sufficient to trigger specific humoral
and cellular immune response similar or even superior to intramuscular vaccination [13–15].
Porcilis1 PRRS is approved in the EU for intradermal application in the neck or along the
muscle of the back using an intradermal device. An alternate application site, like the perianal
region has the potential to increase impact on animal welfare and increase ease of access for
the vaccinator, particularly in sows. However, data on vaccine safety and the resulting immune
response for this application site is limited so far. Therefore, the present study was designed to
assess and compare these parameters after intradermal application of Porcilis PRRS in the
neck and the perianal region of gilts in a commercial farm setting.
Materials and methods
Study design
An empty pig facility was rented in order to conduct the study. At -7 dpv a total of 44 Danish
landrace gilts, purchased from a high health herd, known to be free of PRRSV, M. hyopneumo-
niae and Actinobacillus pleuropneumoniae , confirmed by an actual screening shortly before
study initiation, were included in the study. Gilts were individually ear tagged and were ran-
domly allocated to one of three groups (groups 1, 2 and 3). After one week of acclimatization
(0 dpv), gilts of group 2 (n = 17) were vaccinated intradermally (i.d.) in the neck using a live
attenuated PRRS genotype 1 virus vaccine (Porcilis PRRS, MSD Animal Health, Germany) dis-
solved in Diluvac Forte, according to the manufacturer´s instructions (0.2 ml). For gilts of
group 3 (n = 17), one dose of Porcilis PRRS was administered i.d. (0.2 ml) in the perianal
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region (off-label injection site). Intradermal vaccination was done with a needle free intrader-
mal device (IDAL). The IDAL injector is a battery powered jet injector, equipped with a bottle
holder completed with a spike, in which a vial of vaccine or rinsing fluid is fitted. Vaccination
takes place using the injection head, which is fitted with a mechanical safety cylinder. The
device is capable of delivering a “jet stream” of vaccine (0.2 ml) through the epidermal layers
of the skin. For this purpose the device gives an initial peak force of 2.0–4.2 N to penetrate the
skin followed by a vaccine delivery phase with the force decreasing over time and a drop-off
phase where the force goes to zero (“force curve”). Gilts of group 1 (n = 10) remained unvacci-
nated and served as negative control group. Vaccinated pigs (group 2, 3) and pigs from the
control group were housed in different barns with separate air spaces to prevent transmission
of vaccine virus to control pigs. Clothing, footwear and gloves were changed between rooms
and materials needed for sampling and rectal temperature monitoring were provided sepa-
rately for each room. Animals in both barns were kept under similar conditions in terms of cli-
mate, ventilation, temperature and air humidity. All gilts were group-housed in groups of 17
(group 2, 3) or 10 (group 1) animals on partially slatted floor and space allowance of 2.5 m2/
gilt. The gilts had permanent free access to drinking water and a chain and plastic ball combi-
nation was provided as environmental enrichment material. Fresh air entered through the ceil-
ing and was discharged via a fan in the back of the unit. Artificial light was on from 6 AM to
10 PM. Gilts were fed twice a day with a standard diet for pregnant sows (135 g crude protein,
30 g crude fat, 62 g crude fiber, 54 g crude ash, 12.1 metabolizable energy per kg food) obtain-
ing 2.5 kg feed daily.
General health of all gilts was monitored daily for a period of 28 dpv. For safety assessments,
an individual examination of clinical signs was performed in vaccinated gilts of groups 2 and 3
one day before vaccination, 4h after vaccination and subsequently daily until 15 dpv. Clinical
observation included an assessment of general health, appetite, body condition score, behavior,
respiratory signs and digestion. The rectal temperature was measured with a digital thermome-
ter on the day before and at the time of vaccination, 4 h later and on the consecutive four days.
Injection sites of gilts from groups 2 and 3 were monitored for presence or absence of reactions
including redness, swelling, changes in consistency, necrosis and pain during palpation at day
0 prior to vaccination, 4h post-vaccination and subsequently daily until 28 dpv by the same
observer. Injection site reaction (ISR) parameters (Table 1) and clinical examination were eval-
uated according to a scoring system. Scores were added up and both, a mean cumulative gen-
eral clinical score and ISR score were calculated for each day. Blood samples were collected by
puncture of the jugular vein at -7, 0, 7, 14, 21 and 28 dpv and analyzed for virus-specific anti-
bodies. At 0 dpv, prior to vaccination blood samples of all gilts were analyzed by quantitative
reverse transcriptase PCR (qRT-PCR) as previously described by Kleiboeker et al. [16] to
exclude circulation of field virus. At 7 dpv, samples from gilts of group 1 were investigated by
qRT-PCR to exclude transmission of vaccine virus to the control group. Additionally, ten pigs
per group (n = 30) were randomly selected and heparin stabilized blood samples were collected
at 0, 7, 14, 21 and 28 dpv. Peripheral blood mononuclear cells (PBMCs) were isolated from
these blood samples and used for IFN-γ ELISPOT assays. In addition, the ten randomly
selected blood samples from both vaccination groups (groups 2 and 3; n = 20) were investi-
gated for the presence of PRRSV-specific neutralizing antibodies (nAbs) at 28 dpv. At 28 dpv,
pigs were euthanized by intravenous administration of pentobarbital (Release1, WDT-
Wirtschaftsgenossenschaft Deutscher Tiera¨rzte eG, 45 mg/kg body weight). Gilts from groups
2 and 3 were submitted for necropsy with subsequent microscopic examinations of the appli-
cation site. Furthermore, the contralateral non-treated site of each animal served as control tis-
sue. All procedures were reviewed and approved by the ethics committee of the District
Government of Upper Bavaria under approval code Az.: 55.2-1-54-2532.0-43-14).
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Laboratory analysis
Serology. Sera were analyzed for the presence of PRRSV specific antibodies by means of a
commercial ELISA (IDEXX PRRS X3 Ab Test1, IDEXX Laboratories) using the immunoassay
analyser ThunderBolt™ (Goldstandard Diagnostics U.S.A.) at the laboratory of the Clinic for
Swine, Oberschleissheim, Germany. Results were expressed as sample to positive control (S/P)
optical density ratios. According to the manufacturer, samples with S/P 0.4 were considered
positive.
Virus neutralization tests to determine PRRSV-specific nAbs. The nAbs from the sera
of the vaccinated animals were determined with a fluorescence-based neutralization assay
(FBN-assay) on MA104 cells. Prior to the assay, a defined virus stock solution of Porcilis PRRS
was cultivated for 3 passages on MA104 cells and titrated. For the neutralization assay, MA104
cells (5 x 103 cells/well, 96-well flat bottom, Greiner Bio One, Frickenhausen, Germany) were
cultivated for 2 days in Dulbecco´s Modified Eagle Medium (DMEM) (PAN Biotech, Aiden-
bach, Germany), 10% (v/v) heat-inactivated fetal calf serum (FCS, PAN, Pasching, Austria),
100 IU/mL penicillin and 0.1 mg/mL Streptomycin (both from PAN Biotech) until a 90% con-
fluent cell monolayer was visible. Sera derived from the animal experiment were diluted 1:2
with cell culture medium (DMEM with supplements) and titrated in additional seven log2
steps (up to a dilution of 1:256). Thereafter a PRRSV-stock solution (plaque titer 1.28 x 106 pla-
que forming units (PFU)/mL) was diluted 1:200 with DMEM without FCS to a concentration
of 6.4 x 103 PFU/mL and 100 μL were added to the serum dilutions and incubated for 45 min
at room temperature (RT) (resulting in serum dilutions of 1:4 to 1:512). Thereafter MA104
cells were infected with 100 μL of the pre-incubated PRRSV serum solutions (multiplicity of
infection [MOI] of 0.5). After 1h incubation at 34˚C, 100 μL of DMEM (4% FCS) was added
and the cells incubated for additional 24h at 37˚C.
Thereafter, cells were fixed with 4% paraformaldehyde (100 μL/well, 20 min RT, Merck,
Darmstadt, Germany), permeabilized with 0.1% (w/v) saponin (100 μL/well in phosphate
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buffered saline (PBS), 10 min RT, Sigma-Aldrich) and incubated with a monoclonal antibody
against PRRSV-nucleoprotein (clone P10/b1, IgG1, [17], 50-μL cell culture supernatant, 45
min at RT), followed by two washing steps with PBS and an additional incubation step with
goat-anti mouse IgG1-Alexa488 (Thermo Fisher Scientific, Waltham, MA, 50 μL, 1:200, 30
min RT) and two washing steps. Analyses were performed with a fluorometer (Spectrafluor,
Tecan, Crailsheim, Germany) for the detection of N-protein-specific relative fluorescence
intensities (RFIs). RFIs of the virus control (without nAbs) ranged between 7,000 and 9,000
units and RFIs of the negative control (non-infected) showed around 1000 RFIs. Due to end-
point titrations of the respective sera, nAb titers were determined when RFI values of the
serum dilution reached the RFI level of the untreated virus control.
ELISPOT assay to quantify PRRSV-specific IFN-γ-secreting cells. The numbers of
PRRSV-specific IFN-γ secreting cells (IFN-γ-SCs) were determined in PBMCs. PBMCs were
isolated from heparinized blood samples by density gradient centrifugation (Pancoll human;
density, 1.077 g/ml; PAN Biotech) as described elsewhere [18]. The IFN-γ ELISPOT assay was
performed as previously described [19]. In brief, 96-well plates (MSIPS4510, Merck Millipore,
Darmstadt, Germany) were coated over night with a monoclonal antibody specific for porcine
IFN-γ (Clone pIFN-γ, Mabtech, Nacka Strand, Sweden), adjusted to 10 μg/mL. After washing,
freshly isolated PBMCs were added to wells (3 × 105 PBMCs per well) in RPMI 1640 with sta-
ble glutamine (PAN Biotech) supplemented with 10% (v/v) heat inactivated fetal calf serum
(FCS, PAN Biotech), 100 IU/mL penicillin and 0.1 mg/mL streptomycin (PAN Biotech). Cells
were stimulated with Porcilis1 PRRS vaccine reconstituted in cell culture medium and
adjusted to MOI = 1. Cells cultivated in medium only served as negative control. All samples
were analyzed in triplicates. After 24 h, PBMCs were discarded and plates incubated with a sec-
ond IFN-γ-specific biotinylated antibody (clone PAN, Mabtech, 1 μg/mL) followed by incuba-
tion with streptavidin alkaline phosphatase (Roche, Mannheim, Germany). Finally, 5-bromo-
4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrate (Sigma-Aldrich, Vienna, Aus-
tria) was added for spot development. Spots were enumerated in a camera-based automated
counting system (AID, Straßberg, Germany). Frequencies of IFN-γ SCs were calculated by
subtracting spot numbers of medium-incubated cultures from spot numbers detected after
PRRSV vaccine stimulation.
Histopathologic examination. After fixation of tissue samples in 4% buffered formalde-
hyde solution, paraffin embedding and slicing was performed; 4–5 μm thick slices were stained
by hematoxylin and eosin (HE) and underwent histopathologic evaluation via optical micros-
copy by two independent investigators blinded to the treatments. Furthermore, immunohisto-
chemical staining for T and B cells was performed using antibodies for CD3 (Polyclonal
Rabbit Anti Human CD3, Dako, Glostrup, Denmark) or CD20 (Epitope Specific Rabbit Anti-
body, Dunn Labortechnik GmbH, Asbach, Germany) and CD79a (Mouse Anti-Human
CD79a, Linaris Biologische Produkte GmbH, Dossenheim, Germany) respectively. Scoring of
inflammation was performed in the following manner: (-) no, (+) mild, (++) moderate and (+
++) strong inflammatory reaction. Furthermore, lesion dimension was estimated and the
depth and expansion of invading inflammatory cells in dermal structures was recorded. The
extension of the lesion was estimated in comparison to the whole slice given as percentages (1–
5%, 6–10%, 11–15%, 16-20%, 21–25%, >25%).
Statistical analysis
Sample size calculation was based on Mann-Whitney-U test with α = 0.025 and β = 0.20 using
a case control ratio of 4. Adding a drop out, it revealed n = 17 for both vaccine groups and
n = 10 for the control group based on PRRSV-specific IgG antibody response as primary
Safety and immune responses after intradermal application of Porcilis PRRS
PLOS ONE | https://doi.org/10.1371/journal.pone.0203560 September 7, 2018 5 / 17
variable. Clinical examination score, local ISR score, rectal temperature, PRRSV-specific IgG
antibodies, IFN-γ producing cells in ELISPOT and PRRSV-nAb titers were compared between
study groups by the Mann-Whitney-U test after testing for normal distribution of data. Persis-
tence of local ISR were evaluated in contingency tables with Pearson‘s chi-square tests. Spear-
man rank correlation coefficient was used to determine a correlation between IFN-γ
producing cells and nAb titers. Data were analyzed using IBM SPSS Statistics 22, SPSS Inc., IL,
USA. Significance level was 5% with a 95% confidence interval.
Results
Safety of intradermal vaccination
To assess the safety of an intradermal vaccination of Porcilis PRRS in the perianal region, local
and systemic data were collected from all gilts until 28 dpv. During the observation period
coughing was recorded in one control gilt. Slight tachypnea occurred in both vaccination
groups (group 2: 3 animals, group 3: 4 animals). One animal vaccinated in the neck (group 2)
had reduced feed intake and impaired general health due to lameness of the hind limb. No sig-
nificant differences were found in mean clinical scores between both vaccination groups and
between vaccinated animals and animals of the control group (data not shown). In both vacci-
nated groups the mean rectal temperature remained within physiological range and did not
differ significantly between groups (data not shown).
Local injection site reactions, described as redness and papule with a size of up to 4 mm in
diameter, were recognized in all gilts of both vaccination groups immediately after intradermal
vaccination. The mean total ISR score is displayed in Table 2. At the individual pig level a max-
imum score of 7 out of 12 scoring points was observed in one gilt of group 2 at 24 and 25 dpv
and 9 points in one gilt of group 3 at 16 and 17 dpv. Regarding individual parameters, the
mean diameter of redness was significantly higher in pigs of group 2 (6 dpv: 1.42 cm; 7 dpv:
1.71 cm; 15 dpv: 1.43 cm) compared to pigs of group 3 (6 dpv: 0.71 cm; 7 dpv: 0.86 cm; 15 dpv:
0.55 cm) at 6, 7 and 15 dpv. In gilts that received Porcilis PRRS in the neck the maximum
diameter of redness was 2.77 cm (one gilt, 7 dpv), whereas a maximum diameter of redness of
1.64 cm (one gilt, 4 dpv) was observed in gilts that were vaccinated in the perianal region. At 6,
7, 9 and 14 dpv, more severe swelling was observed in pigs of group 2 (average score for swell-
ing: 6 dpv: 0.53, 7 dpv: 0.59; 9 dpv: 0.41; 14 dpv: 0.41) compared to pigs of group 3 (6 dpv: 0.12;
7 dpv: 0.06; 9 dpv: 0; 14 dpv). The remaining parameters (pain during palpation, necrosis,
induration and degree of redness) did not differ significantly between both vaccination groups
(data not shown). At day 28, the number of pigs with ISR did not differ significantly between
both vaccination groups (group 2: 14/17; group 3: 11/17).
Histopathologic examination revealed inflammatory reactions at the injection site in all
treated animals, whereas none of the control sites had any inflammation. The injection site in
all animals of both groups included one inflammatory focus of variable dimension with several
spots of higher density of cellular infiltrates. Furthermore, foci of necrosis and dystrophic cal-
cification were found in the majority of animals of both vaccination groups (Figs 1 and 2). His-
topathologic findings were accentuated in the papillary layer of the dermis. Single cases (1
perianal and 7 neck injected animals) showed infiltrates reaching the subcutaneous fat tissue.
The extension of the lesion differed significantly (p = 0.002) between both vaccination groups
(median: group 2: 16–20%; group 3: 11–15%). Lymphocytes dominated in inflammatory
lesions, representing both, T and B cells of similar distribution pattern in all animals. Further-
more, plasma cells and some neutrophils and macrophages were detected (data not shown). In
six animals of group 2 and in four animals of group 3, multinucleated giant cells were found in
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the periphery of necrotic foci (data not shown). In addition, in all animals, fibrosis of the injec-
tion site was present.
PRRSV immune responses
To exclude circulation of PRRS field virus as well as transmission of vaccine virus to the con-
trol group qRT-PCR was performed at 0 dpv in samples of all animals and at 7 dpv in samples
of control animals. Blood samples from all gilts were negative for PRRSV RNA by qRT-PCR
Table 2. Comparison of overall local injection site reaction score of both vaccination groups during the study period.
study day score of group 3
(perianal; n = 17)
score of group 2
(neck; n = 17)
p value
mina maxb meanc SDd mina maxb meanc SDd
d-1 0 0 0.00 0.00 0 0 0.00 0.00 1.000
d0 0 0 0.00 0.00 0 0 0.00 0.00 1.000
d0+4 2 3 2.76 0.44 1 3 2.88 0.49 0.433
d1 1 3 2.71 0.69 1 4 2.71 0.85 0.973
d2 1 4 2.53 0.94 1 4 2.76 0.83 0.474
d3 0 4 2.29 0.99 0 4 2.71 1.36 0.099
d4 1 4 2.59 0.71 0 5 2.65 1.41 0.413
d5 1 4 2.59 0.71 0 5 2.76 1.56 0.357
d6 1 4 2.65 0.86 0 5 3.59 1.33 0.013
d7 0 4 2.76 0.90 0 6 3.88 1.41 0.005
d8 0 3 2.41 1.06 0 6 3.47 1.37 0.018
d9 0 3 2.35 1.06 0 6 3.18 1.47 0.034
d10 0 3 2.29 1.05 0 5 3.00 1.37 0.073
d11 0 5 2.47 1.23 0 6 3.18 1.59 0.057
d12 0 6 2.53 1.46 0 6 3.29 1.65 0.150
d13 0 6 2.47 1.46 0 6 3.35 1.66 0.079
d14 0 7 2.41 1.66 0 6 3.35 1.66 0.057
d15 0 7 2.29 1.72 0 6 3.24 1.52 0.038
d16 0 9 2.59 2.12 0 5 3.35 1.58 0.067
d17 0 9 2.65 2.32 0 5 3.18 1.59 0.160
d18 0 8 2.71 2.17 0 6 2.88 1.45 0.540
d19 0 8 2.65 2.15 0 6 3.00 1.54 0.322
d20 0 7 2.59 2.00 0 6 2.94 1.52 0.394
d21 0 6 2.24 1.99 0 5 2.76 1.48 0.306
d22 0 4 2.06 1.43 0 5 2.53 1.28 0.394
d23 0 4 2.06 1.43 0 5 2.59 1.33 0.306
d24 0 4 2.12 1.45 0 7 2.71 1.61 0.394
d25 0 4 2.00 1.46 0 7 2.65 1.69 0.339
d26 0 3 1.76 1.44 0 6 2.59 1.54 0.150
d27 0 3 1.71 1.40 0 6 2.47 1.74 0.182




dstandard deviation (SD) of injection site reaction score of both vaccination groups observed during the entire investigational period.
 indicate statistically significant differences between groups (p 0.05).
https://doi.org/10.1371/journal.pone.0203560.t002
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prior to vaccination and PRRSV RNA could not be detected in gilts of the control group at 7
dpv.
PRRSV-specific ELISA antibody response. The humoral PRRSV immune response was
evaluated in terms of PRRSV-specific antibodies in serum with a commercially available
ELISA. Results are presented in Fig 3. Prior to vaccination, at -7 dpv all gilts were seronegative.
Blood samples from unvaccinated gilts of the control group yielded negative results at all col-
lection time points. Antibodies against PRRSV could not be detected at 0 dpv and 7 dpv in
serum samples of vaccinated pigs (groups 2 and 3). However, at day 14 PRRSV-specific anti-
bodies were present in serum of all vaccinated animals. All gilts from groups 2 and 3 remained
seropositive during the rest of the study. No significant differences were observed in antibody
S/P ratio’s between both vaccination groups.
PRRSV-specific nAbs. To define nAb responses, virus nAb titers were determined by
FBN assay at 28 dpv. NAbs were detected in 8/10 pigs vaccinated in the neck region with titers
ranging from 1:16 to 1:256 (Fig 4). Only 2 gilts reached high titers of 1:256 while nAb titers of
the remaining 6 gilts ranged between 1:16 and 1:64. Due to bacterial overgrowth during incu-
bation, nAbs could not be evaluated in 2 gilts vaccinated in the perianal region. All 8 investi-
gated gilts were positive for nAbs, with titers ranging between 1:16 and 1:512. Gilts vaccinated
intradermally in the perianal region had significantly higher nAb titers than pigs vaccinated
intradermally in the neck (p = 0.043). In contrast, PRRSV-specific nAbs were not detected in
sera from non-vaccinated gilts (group 1).
Frequency of PRRSV-specific IFN-γ secreting cells. To further characterize the immu-
nological response to PRRSV intradermal vaccination, PRRSV-specific IFN-γ SCs were
Fig 1. Representative micrograph for macroscopic examination of neck tissue 28 days after application of Porcilis PRRS.
Micrograph shows focal red discoloration in the dermis with raising of the surface and slight protrusion of the lesion into the
subcutaneous tissue. (Bar = 1cm).
https://doi.org/10.1371/journal.pone.0203560.g001
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measured. At 0 dpv, PRRSV-specific IFN-γ SCs could not be detected in animals from all three
groups (Fig 5). At 7 dpv, low numbers of PRRSV-specific IFN-γ SCs were observed in both
vaccination groups. The frequency of such cells increased further towards 14 dpv in both
groups, although considerable animal to animal variations were observed. At 21 dpv, on aver-
age, a minor decrease of IFN-γ SCs was observed in both groups followed by a rise at 28 dpv.
In contrast, animals from the control group showed no to a very low IFN-γ response with a
maximum of 3 SCs/3 x 105 PBMCs at all investigated time points (data not shown). At 7, 14,
21 and 28 dpv the number of IFN-γ SCs in both vaccination groups (group 2, 3) were signifi-
cantly different as compared to the control group (group 1). The number of PRRSV-specific
IFN-γ SCs tended to be higher in pigs vaccinated in the neck compared to gilts vaccinated in
the perianal region. However, no significant differences between both vaccination groups were
observed at any of the investigated time points (7, 14, 21, 28dpv) (p<0.05).
Association between nAb response and IFN-γ secreting cells. The frequency of PRRSV-
specific IFN-γ SCs/3 x 105 PBMCs was compared to the nAbs of individual animals. Interest-
ingly, there were no detectable levels of nAbs in two animals 28 dpv despite their IFN-γ
response. Comparison of PRRSV-nAb titers and IFN-γ SCs suggested that animals with low
Fig 2. Histopathological changes of tissues samples of the neck and the perianal region 28 days after application of Porcilis PRRS. A) HE stained slides of control
tissue (contralateral, non-treated site of neck [left] and perianal region [right]) without any inflammation. B) HE stained slides of the neck [left] and perianal application
[right] sites: moderate inflammation with fibrosis and cellular infiltrates reaching the subcutaneous fat tissue. Abbreviations: E = Epidermis, D = Dermis,
SF = Subcutaneous fat tissue; 1 = Inflammatory focus, 2 = Inflammatory cellular infiltration with multifocal necrosis and dystrophic calcification. Representative slides
of the different treatment groups are shown.
https://doi.org/10.1371/journal.pone.0203560.g002
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PRRSV-nAb titers had higher IFN-γ SCs than animals with high PRRSV-nAb titers. Hence, no
positive correlation was observed between nAb titers and the number of IFN-γ SCs
(p = 0.542).
Fig 3. PRRSV-specific antibody titers (S/P ratios) by ELISA in the time course of the different groups. S/P ratio for non-vaccinated
gilts (group 1), gilts that received intradermal PRRSV vaccination into the neck (group 2) and sows that received intradermal PRRSV
vaccination into perianal region (group 3) are shown. Mean S/P ratios for the three different groups ± standard deviations are shown.
https://doi.org/10.1371/journal.pone.0203560.g003
Fig 4. Comparison of PRRSV-nAb titers of vaccinated animals 28 dpv. Each symbol represents nAb titer of one
individual animal vaccinated intradermally, either into the neck (group 2) or into the perianal region (group 3). Black
bars represent mean values within each group.
https://doi.org/10.1371/journal.pone.0203560.g004
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Discussion
Although several studies have shown that intradermal application of an attenuated PRRSV
vaccine in the neck can efficiently induce a protective immune response [13, 14], up to date no
studies are available investigating safety and efficacy of different application sites. As the neck
is the most common site of mainly intramuscular injection of breeding stock an alternative
application site could reduce stress for the animal and simplify the application process for the
user. Therefore, the present study was designed to evaluate safety and humoral and cellular
immune responses in gilts after intradermal vaccination with Porcilis PRRS in the perianal
region. Since efficacy of intradermal vaccination of Porcilis PRRS in terms of clinical protec-
tion has been demonstrated in a previous study [13] no experimental infection was considered
for the present study. Additionally, for ethical considerations regarding reduction of animals
used in experiments an intramuscular group was not included in the study design as results
from previous studies indicate that Porcilis1 PRRSV administered via the intradermal route
can efficiently induce a protective immune response comparable or in some cases higher than
the intramuscular route.[13–15, 20].
With respect to safety, no significant differences were found in frequency and degree of
clinical signs between both vaccination groups and between vaccinated animals and control
animals. In accordance with other studies, the intradermal application of Porcilis PRRS
induced no systemic reactions, nor an increase in rectal temperature [14]. Local ISR were
observed in both vaccination groups until 28 dpv. In contrast, in a recent study, ISR after intra-
dermal application of Porcilis PRRS were resolved by 28 dpv [21]. However, in consistency
with other studies, using the intradermal route of vaccination, the observed ISR were of minor
degree [20, 22, 23]. In the present study, alterations of the skin were significantly more severe
on 6, 7, 8, 9 and 15 dpv in pigs vaccinated intradermally in the neck compared to pigs vacci-
nated in the perianal region. As local reactions at the injection site could be associated with
pain, vaccination in the perianal region might improve animal welfare. The overall degree and
type of inflammation detected by histopathological examination was comparable between
both vaccination groups. However, the extent of the inflammation was higher in the pigs vacci-
nated in the neck compared to perianal injected pigs. The differences in the extent of inflam-
mation between both vaccination groups reflects the tendency of higher macroscopic injection
site scores observed in pigs vaccinated in the neck. According to the literature, the penetration
depth might vary between different application sites due to skin variability (i.e. skin thickness,
skin surface, hair density) [24]. Therefore, the site of application seems to have an effect on
grossly visible reaction levels and lesion extension at the injection site.
Fig 5. Frequency of PRRSV-specific IFN-γ producing PBMCs analyzed by ELISPOT. The consecutive graphs show
the frequency of IFN-γ SCs in animals vaccinated intradermally into the neck (group 2) and animals vaccinated
intradermally into the perianal region (group 3). Each symbol represents the frequency of IFN-γ producing cells of
individual animals within 3 × 105 PBMCs. Black bars represent mean values within each group per study day.
https://doi.org/10.1371/journal.pone.0203560.g005
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Vaccination with the intradermally administered vaccine evoked a PRRSV-specific anti-
body response measured by ELISA in all (34/34) animals from both vaccination groups on 14
dpv. Despite the fact that these results are in agreement with previous studies [14], it is well
accepted that the concentration of serum antibodies measured by ELISA cannot be regarded
as correlates of protective immunity against PRRSV [25–27]. In contrast, the cell mediated
immune response in terms of frequency of IFN-γ SCs has been widely used to evaluate vaccine
efficacy [13, 28–32]. According to Zuckermann et al. [29] the IFN-γ response can be used as
indicator of protective immunity and also Martelli et al. [13] demonstrated a clear association
between clinical protection and the kinetics of the cell mediated immune response. Similarly,
Lowe et al. [30] showed that the number of IFN-γ producing cells measured by ELISPOT was
correlated with protection against PRRSV in three of four commercial herds experiencing out-
breaks of PRRSV and results from Diaz et al. [33] indicate a strong involvement of IFN-γ in
the development of immunity against PRRSV. Also, Charerntantanakul et al. [28] showed that
expression of IFN-γ by several T-cell subsets correlated with reduced lung lesions and viremia.
Due to these previous findings, a challenge infection was not performed in our study, instead,
we considered the simultaneous analysis of PRRSV-specific IFN-γ producing lymphocytes and
nAbs (see also below) as adequate read-outs to evaluate vaccine efficacy. In previous studies
intradermal administration of PRRSV vaccines provoked an IFN-γ response similar or even
superior to the application via the intramuscular route [13, 15]. In the present study, a minor
increase in IFN-γ SCs was detected in some pigs from both vaccination groups as early as 7
dpv. On 14 dpv, IFN-γ-SCs were evident in the vast majority of animals from both vaccination
groups. In contrast, a different study investigating the intradermal route of PRRSV vaccination
found a lower percentage of animals with PRRSV-specific IFN-γ-SCs at 14 dpv [13]. After 14
dpv, a further increase of IFN-γ SCs was observed in the present study. However, individual
animals reached a maximum level at day 14, followed by a decline of IFN-γ SCs at 21 dpv and
a subsequent increase at the end of the observational period (28 dpv). This is in contrast to
other studies describing a gradual increase in the frequency of IFN-γ SCs [32]. However,
biphasic IFN-γ SCs kinetics have also been observed by others [33, 34] and might be attributed
to the highly variable IFN-γ SCs response among individual animals that has been observed in
our study and also by others [34, 35]. According to Ferrari et al. [15], pig to pig variation was
greater in pigs vaccinated intradermally compared to pigs vaccinated intramuscularly. Results
from a recent study suggest that inter-individual variability in markers of PRRSV vaccine-
induced immunity, including nAb levels and IFN-γ responses, may be regulated by host
genetic factors [36]. Nevertheless, the mean number of IFN-γ SCs did not differ significantly
between both vaccination groups. The intensity of the IFN-γ response observed in our study is
consistent with the results obtained in previous studies [13, 15, 29]. In general, the frequency
of IFN-γ SCs is reported to be low after vaccination or infection [13, 15, 29]. However, results
from Klinge et al. [37] indicated that inoculation with virulent PRRSV strains elicits a higher
number of IFN-γ SCs than inoculation with a modified live virus vaccine. It has to be kept in
mind though that a comparison of IFN-γ SCs between different studies has to be done with
caution as results are influenced by inter-assay variability caused by differences in restimula-
tion time, MOI, type of antigen used for restimulation, the particular PRRSV strain used for
infection and re-stimulation, as well as the immune status and the age of the pig [37]. In the
present study vaccine virus was used as the recall virus in order to perform a homologous re-
stimulation. According to our experience and in-house data, IFN-γ SCs in vaccinated pigs are
induced after re-stimulation with homologous vaccine virus as well as with heterologous field
virus (data not published). These findings can be explained by data of Mokhtar et al. [38], who
used a peptide library spanning the entire PRRSV proteome in order to analyze the antigen
Safety and immune responses after intradermal application of Porcilis PRRS
PLOS ONE | https://doi.org/10.1371/journal.pone.0203560 September 7, 2018 12 / 17
specificity of T cell responses. The authors could identify highly conserved epitopes present
within different PRRSV isolates.
Although several authors have highlighted the importance of nAbs for protective immunity
against PRRSV [26, 27, 39] the role of nAbs in clearance of viremia and protection against the
disease has been discussed controversially [40–42]. Results from a previous study indicate that
protection is dependent on the amount of nAbs. However, age dependent differences have to
be considered since higher concentrations of nAbs are needed to obtain sterilizing immunity
in young piglets than in sows [43]. According to previous reports attenuated PRRSV vaccines
induce a non-detectable or low nAb response, particularly if pigs are only vaccinated once [29,
44–46]. Ferrari et al. [20] did not observe nAbs in pigs vaccinated intramuscularly or intrader-
mally with a modified live PRRSV vaccine prior to challenge (0–35 dpv). In contrast, the
majority of pigs in our study (16/18) had nAbs at 28 dpv. Additionally, it is worth noting that
high titers of nAbs were detected in the present study. However, it has to be kept in mind that
nAb titers from different studies cannot be directly compared due to several factors influenc-
ing the outcome, like e.g. the particular PRRSV strain, the conditions of virus culture, visuali-
zation method, etc. In the present study, gilts vaccinated intradermally in the perianal region
had significantly higher PRRSV-nAb titers than pigs vaccinated intradermally in the neck.
Interestingly, two animals of the neck group did not develop nAbs on 28 dpv despite having
medium to high numbers of PRRSV-specific IFN-γ SCs. As nAbs are known to appear late
after infection/vaccination, typically 28 days [32, 47], the lack of nAbs at 28 dpv might be
attributed to their delayed development. It is fairly remarkable that in contrast to previous
reports [20, 34], no association was observed between virus nAbs and IFN-γ-SCs levels under
the condition of this study. This might be explained by the short investigational period of 28
days. However, it seems more likely that this observation was mainly attributed to the extreme
variability of IFN-γ SCs response observed among individual animals.
Conclusion
Several studies have been conducted comparing humoral and cellular immune responses
induced by intramuscular and intradermal PRRSV vaccination. However, up to date investiga-
tions on the compatibility of different intradermal application sites are lacking. As the neck is
routinely used for vaccination, an alternative application site is highly desirable to improve
welfare of animals. Results from the present study strongly suggest that the perianal region
could be a safe application site and that the intradermal application of Porcilis PRRS in the
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